Theriva™ Biologics宣布,已获得监管授权,将推进一项名为Virage2的2a期临床试验。该试验旨在评估其候选药物VCN-01(Zabilugene Almadenorepvec)在转移性胰腺导管腺癌一线治疗患者中,采用更频繁给药方案的安全性与疗效。
Theriva™ Biologics宣布,已获得监管授权,将推进一项名为Virage2的2a期临床试验。该试验旨在评估其候选药物VCN-01(Zabilugene Almadenorepvec)在转移性胰腺导管腺癌一线治疗患者中,采用更频繁给药方案的安全性与疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.